March 26, 2018 / 12:42 PM / a month ago

BRIEF-Ampio Primary Endpoint Was Change In Womac A Pain Between Baseline And Week 20​

March 26 (Reuters) - Ampio Pharmaceuticals Inc:

* EVIDENCE FOR DELAY OF TOTAL KNEE REPLACEMENT (TKR) FOR PATIENTS WITH SEVERE OSTEOARTHRITIS OF THE KNEE RECEIVING THREE INTRA-ARTICULAR (IA) AMPION™ INJECTIONS

* AMPIO PHARMACEUTICALS INC - ‍PRIMARY ENDPOINT WAS CHANGE IN WOMAC A PAIN BETWEEN BASELINE AND WEEK 20​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below